Non-invasive ablation of arrhythmias with stereotactic ablative radiotherapy

Stereotactic ablative radiotherapy (SABR), or stereotactic body radiotherapy (SBRT), has recently been applied in the field of arrhythmia management. It has been most widely assessed in the treatment of ventricular tachycardia (VT) but may also have potential in the treatment of other arrhythmias as well, often termed stereotactic arrhythmia radiotherapy (STAR). The non-invasive delivery of treatment for VT has the potential to spare an often physiologically vulnerable group of patients the burden of long catheter ablation procedures with the potential for prolonged periods of hemodynamic instability. Cardiac SABR also has the capacity to direct ablative therapy at substrate that is inaccessible using current transchatheter techniques. For these reasons cardiac SABR has generated significant enthusiasm as an emerging treatment modality for VT. We consider in review the pre-clinical data pertaining to the use of SABR in cardiac tissue and recent clinical evidence regarding the application of SABR in the field of arrhythmia management.(C) 2021 Elsevier Inc. All rights reserved.

Automated summary

Stereotactic ablative radiotherapy (SABR) has been increasingly used in the management of arrhythmias, particularly ventricular tachycardia (VT). It offers a non-invasive treatment option that can spare patients from lengthy catheter ablation procedures and target substrate that is inaccessible using current techniques. Both pre-clinical and clinical evidence support the potential of cardiac SABR in arrhythmia management.